The FDA has accepted a new drug application for aficamten, a new obstructive hypertrophic cardiomyopathy drug. A goal date ...

Favorable short- and long-term outcomes are seen in patients with hypertrophic cardiomyopathy who receive septal reduction therapy.

Methods: Members of the Hypertrophic Cardiomyopathy Association ... demographic and self-reported clinical information, and types and triggers of symptoms. Respondents reported physical and ...

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to ...

The implementation of a risk evaluation mitigation strategy (REMS) program to monitor patients on mavacamten further supports its real-world use, according to Milind Desai, MD, Cleveland Clinic.

Cytokinetics, Bayer enter collaboration and licensing pact to develop & commercialize aficamten in Japan: South San Francisco, California Wednesday, November 20, 2024, 15:00 Hrs [ ...

This ultimately limits the heart's pumping function, resulting in reduced exercise capacity and symptoms ... pivotal Phase 3 clinical trial evaluating aficamten, a next-in-class cardiac myosin ...

Describes the nature of a clinical study. Types include ... LV end-diastolic wall thickness that meets a threshold of: Z-score > 2.5 in the absence of symptoms or family history or Z-score > 2 in the ...

The groundbreaking treatment works by reducing excessive contraction of the heart muscle in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This award is presented ...

With Danon disease, which is thought to account for about 5% of pediatric forms of hypertrophic cardiomyopathy, symptoms usually ... fact that therapy had a net clinical benefit and delayed ...